Ahead of the busiest week for biopharma dealmaking at the annual JP Morgan Healthcare Conference, a new startup launched, ...

Aspect Biosystems raises $115M Series B for bioprinted tissue therapeutics targeting diabetes and metabolic disorders, led by ...

Tenvie Therapeutics launches with $200M, acquires Denali drug candidates, led by Tony Estrada with NLRP3 and SARM1 inhibitors ...

Roche's Chugai partners with Araris Biotech on multi-payload ADCs, as Swiss biotech advances tech allowing multiple cytotoxic ...

Galapagos is looking for a fresh start after a rough few years. The Belgian biotech has outlined plans to branch off into two ...

Jasper Therapeutics continued building out the data for a drug designed to treat irritable skin conditions, though the latest ...

Novo Nordisk is doubling down on its computational biotech partner Valo Health, expanding their collaboration from 11 ...

Maze Therapeutics has submitted its pitch for an initial public offering after disclosing a $115 million Series D, forging a ...

Sanofi has enlisted drug discovery company Alloy Therapeutics to develop an antisense oligonucleotide drug for a single, undisclosed central nervous system target.

Aet­na is go­ing af­ter an­oth­er phar­ma­ceu­ti­cal com­pa­ny for al­leged price fix­ing. The health in­sur­ance provider ...

New an­ti-obe­si­ty drugs should meet a min­i­mum lev­el of weight loss to be con­sid­ered for ap­proval, the FDA said ...

Bayer’s Nexavar and Boehringer Ingelheim's Spiriva are among a handful of drugs with reduced US list prices for the new year, ...